Fulfilling Potential In the Treatment of Gastrointestinal and Rare Diseases


Alcresta Therapeutics is a company dedicated to developing and commercializing novel enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency, which results in malabsorption common in cystic fibrosis, digestive cancers, premature birth and other serious diseases. The company’s lead product, RELiZORB™, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral tube feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). The importance of long-chain polyunsaturated fatty acids like omega-3 is well documented across the full spectrum of patient care from infants to adults and individuals battling acute conditions or chronic diseases.


Year Invested: 2011
Location: Newton, Mass.
Visit: www.alcresta.com

Recent News

September 20, 2017
Alcresta Therapeutics Receives New Innovative Technology Contract from Vizient, Inc. For RELiZORB® (iMMOBILIZED LIPASE) Cartridge

July 31, 2017
Alcresta Therapeutics Announces Positive Results, RELiZORB® Increased Fat Absorption in Both Adult and Pediatric Patients with Cystic Fibrosis Receiving Enteral Nutrition

July 20, 2017
Alcresta Therapeutics Receives 510(K) Clearance For Use of RELiZORB® in Children

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner

Kevin Gillis
Partner/Chief Financial Officer